Skip to main content

Table 4 Summary of immunogenicity in men and women receiving TIV in the immunogenicity set.

From: Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

Year

Antigen

Parameter

Men

value (95% CI)

N = 482

Women

value (95% CI)

N = 816

Season 1

A/H1N1

% Seroconversion

72 (67, 77)

66 (62, 70)

2005-6

 

Day 21 GMT

385.9 (334.6, 445.1)

385.1 (344.4, 430.7)

  

Day 21% ≥ 40

98 (96, 99)

96 (95, 98)

 

A/H3N2

% Seroconversion

85 (81, 89)

85 (82, 88)

  

Day 21 GMT

265.4 (231.0, 305.0)

254.4 (227.7, 284.2)

  

Day 21% ≥ 40

95 (93, 97)

93 (91, 95)

 

B

% Seroconversion

83 (79, 87)

81 (77, 84)

  

Day 21 GMT

329.6 (291.3, 373.0)

304.6 (275.8, 336.4)

  

Day 21% ≥ 40

99 (98, 100)

98 (96, 99)

Season 2

A/H1N1

% Seroconversion

72 (65, 79)

65 (59, 71)

2006-7

 

Day 21 GMT

414.2 (337.0, 508.9)

318.6 (269.7, 376.3)

  

Day 21% ≥ 40

99 (97, 100)

98 (96, 99)

 

A/H3N2

% Seroconversion

67 (60, 74)

75 (69, 80)

  

Day 21 GMT

141.9 (117.7, 171.1)

168.3 (145.1, 195.3)

  

Day 21% ≥ 40

90 (86, 95)

93 (90, 96)

 

B

% Seroconversion

73 (66, 80)

74 (69, 80)

  

Day 21 GMT

290.9 (244.8, 345.7)

296.8 (257.2, 342.5)

  

Day 21% ≥ 40

97 (95, 100)

97 (95, 99)

  1. GMT, geometric mean titer